

OKLAHOMA BOARD OF NURSING
2915 N. Classen Boulevard, Suite 524
Oklahoma City, Oklahoma 73106

**CRNA Formulary Advisory Committee
Minutes-April 27, 2015**

The CRNA Formulary Advisory Council (“Council”) to the Oklahoma Board of Nursing (“Board”) met on April 27, 2015. Notice of the meeting was initially filed with the Secretary of State’s Office on December 4, 2014. Notice of the meeting was posted on the Oklahoma Board of Nursing web site. A notice/agenda was also posted on the Cameron Building front entrance at 2915 North Classen Boulevard, Oklahoma City, Oklahoma, as well as the Board office at 2915 North Classen, Suite 524, at 8 AM on April 22, 2015 and not less than 24 hours prior to the meeting.

Place of Meeting: Basement Conference Room, Cameron Building

Time of Meeting: 3:30 PM

Members Present: Mark St Cyr, D.Ph.
Oklahoma Pharmacists Association

Bruce Kennedy, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Victor Long, APRN-CRNA
Oklahoma Association of Nurse Anesthetists

Ervin Yen, MD (arrived at 4:18 PM)
Oklahoma Society of Anesthesiologists

Thomas Tinker, MD
Oklahoma Society of Anesthesiologists

Members Absent: None

Board Representative: Mandy Nelson, MS, APRN-CNS

Staff Representatives: Jackye Ward, MS, RN
Gina Stafford, RN

Guest: Nancy Sweet-Fitzgibbon, APRN-CRNA

1.0 Call to order: The meeting was called to order at 3:30 PM by Bruce Kennedy, Chairperson.

1.1 Declaration of a quorum: A quorum was declared present.

2.0 Minutes of the previous meeting – April 28, 2014: The minutes were reviewed. A motion was made (Victor Long) and seconded to approve the minutes of April 28, 2014.

Voting:

Yes: (4) M. St Cyr, B. Kennedy, V. Long, T. Tinker
No: (0)
Absent: (1) E. Yen (arrived after voting)

Motion Carried.

3.0 Board of Nursing update (verbal reports requiring no action by Committee):

- 3.1 Proposed amendments to the Oklahoma Nursing Practice Act: Jackye Ward summarized House Bill 1081 and proposed changes related to the *Oklahoma Nursing Practice Act*. The bill was signed by the Governor on April 21, 2014 and will become effective November 1, 2015.
- 3.2 Revisions to the Rules of the Oklahoma Board of Nursing: Jackye Ward reported on revisions approved by the Board to the *Oklahoma Board of Nursing Rules*. The *Rules* will go through the legislative process.
- 3.3 Gina Stafford reviewed recent revisions to the *Exclusionary Formulary for Advanced Practice Registered Nurses with Prescriptive Authority and Formulary Advisory Council Procedure for Amending the Formulary*.
- 3.4 Gina Stafford reviewed the brochure, *Oklahoma Health Care Provider's Responsibilities and Rights Under Medical Treatment Laws*. [63 O.S. § 3162]
- 3.5 Gina Stafford reviewed the statutes regarding the CRNA Formulary Advisory Council. [59 O.S. § 567.4b]
- 3.6 CRNA Formulary Advisory Council appointment expirations: Dr. Yen's appointment will expire 4/30/2015. The other council members will not expire before the next meeting. Contact will be made with the Oklahoma Society of Anesthesiologist for the appointment of a representative.

4.0 Review and committee recommendations on revisions to CRNA Inclusionary Formulary: Council members reviewed the DRAFT *CRNA Inclusionary Formulary*, #P-50 with proposed revisions. A list of new and updated monographs was provided to committee members. The proposed revisions add new cross-references; identify drugs that remain on the market but for which no monograph is provided in the current edition of the *AHFS Drug Information Manual*; and change the Hetastarch cautionary statement. Also, the committee discussed changes to the cautionary statement regarding the use of Promethazine Hydrochloride; the possible addition of Vilanterol, Perphenazine, Tranexamic (TXA) and Aprepitant; and the deletion of Chloral Hydrate and Pentastarch.

After discussion, it was moved (Bruce Kennedy) and seconded to submit the following revisions to the *CRNA Inclusionary Formulary*, #P-50 to the Board for approval:

- Add additional cautionary language regarding IV use of Promethazine Hydrochloride including the FDA boxed warning
- Addition of Levalbuterol 12:12.08.12
- Addition of Tranexamic (TXA) 20:28.16

- Addition of Perphenazine 28:16.08.24
- Addition of Antiemetics, Aprepitant 56:22.92
- Change 12:00 Autonomic Agents to Autonomic Drugs
- Add an asterisk to denote that the information on the following drugs has been omitted from the print version of *AHFS Drug Information*:
 - Scopolomine 12:08.08
 - Midodrine 12:12.04
 - Metaraminol 12:12.12
 - Esmolol Hydrochloride 24:24
 - Nalbuphine 28.08.12
 - Ethotoin 28:12:12
 - Perphenazine 28:16.08.24
 - Sodium Lactate 40.08
 - Dextran 40:12
 - Trimethobenzamide 56:22.08
 - Cimetidine 56:28.12
 - Insulin Zinc 68:20.08
 - Chlorpropamide 68:20.20
 - Chlorhexiden gluconate 84:04.92
- Remove asterisk on the following drugs now included in the print version of *AHFS Drug Information*:
 - Methylene Blue 92:12
 - Vasoconstrictors 52:32
- Removal of Chloral Hydrate 28:24.92
- Removal of Pentastarch 40:12 and warning
- Update the reference for *AHFS Drug Information* to the current edition (2015)

Voting:

Yes: (5) M. St Cyr, B. Kennedy, V. Long, T. Tinker, E. Yen
 No: (0)
 Absent: (0)

Motion Carried.

5.0 Election of Chairperson and Vice Chairperson for 2016: It was moved (E. Yen) and seconded to appoint Thomas Tinker as Chairperson. It was moved (V. Long) and seconded to appoint B. Kennedy as Vice Chairperson for the next CRNA Formulary Advisory Council Meeting.

Voting:

Yes: (5) M. St Cyr, B. Kennedy, V. Long, T. Tinker, E. Yen
 No: (0)
 Absent: (0)

Motion Carried.

6.0 Date for next meeting: The members discussed possible dates and times for the next meeting.

6.1 Selected date and time for the next meeting will be Monday, April 25, 2016, at 3:30 PM.

7.0 Adjournment: There being no further business, the meeting was adjourned at 4:30 PM.